Related Experiment Video
Updated: Feb 13, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
MicroRNA-Based Drugs for Brain Tumors
Shubaash Anthiya1, Audrey Griveau2, Claire Loussouarn3
1CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France; INSERM U1232, Team-17, GLIAD - Design and Application of Innovative Local treatments in Glioblastoma, Université d'Angers, IBS - CHU, 4 Rue Larrey, 49933 Angers, France; School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK; These authors contributed equally to this work.
Trends in Cancer
|March 7, 2018
Summary
MicroRNAs (miRNAs) regulate genes and are crucial in cancer. This review explores miRNA biogenesis, cancer resistance roles, and therapeutic delivery systems for glioblastoma treatment.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- MicroRNAs (miRNAs) are genomic regulatory elements controlling multiple genes.
- Cancer involves numerous gene aberrations, necessitating novel therapeutic strategies.
- Glioblastoma (GBM) presents complex genetic challenges in cancer treatment.
Purpose of the Study:
- To summarize miRNA biogenesis and its role in cancer resistance.
- To review tools for modulating miRNA expression.
- To discuss RNA interference (RNAi) delivery systems for GBM therapy.
Main Methods:
- Literature review of miRNA biogenesis and function.
- Analysis of miRNA's role in cancer resistance mechanisms.
- Evaluation of current and emerging miRNA modulation tools.
- Assessment of RNAi delivery systems for clinical application.
Main Results:
- miRNAs are critical regulators with implications in diverse cellular functions.
- Dysregulated miRNAs contribute to cancer development and resistance.
- Various tools exist for modulating miRNA expression, offering therapeutic potential.
- RNAi delivery systems show promise for targeted cancer therapies, including GBM.
Conclusions:
- Understanding miRNA pathways is vital for advancing cancer treatment, particularly for GBM.
- Modulating miRNA expression and utilizing effective delivery systems are key therapeutic avenues.
- Further research into miRNA-based therapies could revolutionize cancer care.
Keywords:
RNAiargonautebrain targetingcancer resistancedrug deliveryexosomesglioblastomananoparticlesMore Related Videos
Related Concept Videos
01:22MicroRNAs
24.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
01:22MicroRNAs
4.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
231
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
231
01:30Drug toxicity: Drug–Drug Interaction
2
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
2
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K